Proactive investors

Silence Therapeutics plc (LSE: SLN) is a global leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses one of the world’s most comprehensive RNAi therapeutic platforms comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features – the three areas the company believes to be critical to building, protecting and commercialising RNAi therapeutics. This platform is protected by Silence’s strong intellectual property portfolio which includes more than 200 issued and pending patent applications worldwide. Additionally, Silence is a clear leader in the development of RNAi clinical candidates, possessing a pipeline that includes a total of five different internal and partnered programs in the clinic.  A final key validation of Silence’s leadership position in RNAi is the company’s multiple major partnerships with global pharmaceutical companies.  The partnerships with companies such as AstraZeneca, Pfizer, Quark Pharma and Dainippon Sumitomo further demonstrate the credibility of Silence’s technologies.

The company possesses one of the most comprehensive and sophisticated RNAi therapeutic platforms comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features – the three areas the company believes to be critical to building, protecting and commercializing RNAi therapeutics. This platform is protected by Silence’s strong intellectual property portfolio which includes more than 200 issued and pending patent applications worldwide.

Additionally, Silence is a clear leader in the development of RNAi clinical candidates, possessing a pipeline that includes a total of five different internal and partnered programs in the clinic.  With at least half of the siRNA programs currently in clinical development worldwide based on Silence's technology, the company’s clinical pipeline validates not only the strength of the company's proprietary technology but also the team of researchers that has guided the development path.

A final key validation of Silence’s leadership position in RNAi is the company’s multiple major partnerships with global pharmaceutical companies.  The partnerships with companies such as AstraZeneca, Pfizer/Quark Pharma and Dainippon Sumitomo further demonstrate the credibility of Silence’s technologies.

Board of Directors

JERRY RANDALL
Position: Chairman
Mr. Randall is a qualified chartered accountant and previously served as the chief financial officer of Sinclair Pharmaceuticals plc which he joined in 2000 as part of a management buy-in team. Prior to this, Mr. Randall worked in corporate finance with Gambit Corporate Finance and had previously been involved in two other buy-ins. He acted as adviser to both private and quoted companies between 1993 and 2000, in both the capacity of nominated adviser and in practice with KPMG. During this period, he was involved in a number of flotations and transactions on the Official List, Unlisted Securities Market and the Alternative Investment Market, as well as raising private equity.

ANNETTE CLANCY
Position: Non-Executive Director
Ms. Clancy has had a distinguished career spanning 30 years with GlaxoSmithKline (GSK). She has 15 years experience in business development, leading GSK's global transactions and alliance management teams for the past three years, and during her tenure she and her team have been responsible for concluding a large number of research, development and commercial business collaborations on behalf of GSK. Prior to her role in business development, Ms. Clancy held a number of positions in clinical research, research and development project management and commercialization. Ms. Clancy has a BSc (Hons) in pharmacology from Bath University.

PHILIP HAWORTH, JD, Ph.D.
Position: Chief Executive Officer
Dr. Haworth was appointed chief executive officer of Silence Therapeutics in January 2010, following the company’s merger with Intradigm Corporation.  Prior to this role, Dr. Haworth served as CEO of Intradigm, following his tenure as the company’s vice president of business development. He joined Intradigm in 2007, having spent the previous 15 years in senior business development roles at several leading biotechnology companies including Genencor International, COR Therapeutics and Affymax/Affymetrix, among others. In these positions, he led the identification and negotiation of numerous collaborative and licensing agreements with a range of global and regional pharmaceutical companies. He most recently served as vice president, business development at Codexis, Inc. He possesses deep deal–making expertise that spans establishing discovery and development partnerships, technology and product in– and out–licensing, mergers and acquisitions, and financing support.

Dr. Haworth earned his J.D. from Stanford University Law School and his Ph.D. in biochemistry from the University of Manchester in the U.K. He also received his bachelor’s degree with first class honors in physiology and biochemistry from the University of Southampton in the U.K.

JAMES N. TOPPER, M.D., Ph.D
Position: Non-Executive Director
Dr. Topper is a general partner at Frazier Healthcare Ventures’ Palo Alto office and was the chairman of the board of Intradigm from May 2006 to the date of the merger with Silence Therapeutics. Since joining Frazier Healthcare in 2003, Dr. Topper has led several biopharma investments including Arête Therapeutics, Cotherix, and MacuSight. Dr. Topper is also an advisory board member to the Harvard-Partners Center for Genetics and Genomics. Prior to joining Frazier Healthcare, he served as head of the cardiovascular research and development franchise at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Prior to the merger of COR and Millennium, he served as the Vice President of Biology at COR and was responsible for managing all of its research activities.

Dr. Topper received his MD and Ph D in Biophysics from Stanford University School of Medicine in 1991. He completed his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women’s Hospital in Boston and is board certified in both disciplines. While there, he completed a research fellowship in the Vascular Research Division in the department of Pathology. He then joined the faculty of Harvard Medical School from 1997 to 1998, and subsequently Stanford University as an Assistant Professor of Medicine (Cardiovascular) in July 1998. He has authored over 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford University. He continues to hold an appointment as a Clinical Assistant Professor of Medicine at Stanford University.

DAVID MACK, Ph. D
Position: Non-Executive Director
Dr. Mack is a director at Alta Partners where he led the investment in Angiosyn as a director and acting CEO (acquired by Pfizer in 2005). He joined Intradigm’s board in May 2006 and served on that board until the merger with Silence Therapeutics. He is currently on the board of directors of Aerie Pharmaceuticals, Ceregene and Proacta. Prior to Alta, Dr. Mack co-founded and served as Vice President of Genomics Research at Eos Biotechnology (acquired by Protein Design Labs in 2003). From 1995 to 1997, he served at Affymetrix as Head of Cancer Biology where he oversaw the development and application of DNA array technology in the areas of oncology and inflammation. He was also a pivotal member of the Polymerase Chain Reaction (PCR) invention group at Cetus (now Chiron) in the mid 1980s.

Dr. Mack has co-authored more than 30 scientific articles and reviews, including papers published in Cell, Science and Nature, and he is an inventor on 21 US patents. He was an American Cancer Society postdoctoral fellow at Stanford University School of Medicine in Microbiology and Immunology. Dr. Mack received his Ph.D. in 1992 from the University of Chicago where he was a Howard Hughes fellow in Molecular Genetics and Cell Biology. He holds a Bachelor of Arts in Molecular Biology from University of California, Berkeley.

DAVID U'PRICHARD, Ph.D.
Position: Non-Executive Director
Dr. U'Prichard was, from 1999 to 2003, chief executive officer and a member of the board of directors of 3-Dimensional Pharmaceuticals, Inc. ("3DP"). During that time, he took 3DP public and secured large collaborations with Bristol-Myers Squibb and Johnson & Johnson. In March 2003, 3DP become a part of Johnson & Johnson Pharmaceutical R&D. From 1997 to 1999, Dr. U'Prichard served as chairman of research and development at SmithKline Beecham. While at SmithKline Beecham, Dr. U'Prichard oversaw the entry of approximately ten compounds into global development, the international registration of the diabetes drug Avandia® and the entry of four compounds into Phase III trials and six compounds into early clinical trials; additionally, he instituted several major restructuring efforts at the company. Prior to SmithKline Beecham, he worked for ICI/Zeneca from 1986 to 1997, as executive vice president and international research director from 1994 to 1997.

Senior Management Team

PHILIP HAWORTH, JD, Ph.D.
Position: Chief Executive Officer
Dr. Haworth was appointed chief executive officer of Silence Therapeutics in January 2010, following the company’s merger with Intradigm Corporation.  Prior to this role, Dr. Haworth served as CEO of Intradigm, following his tenure as the company’s vice president of business development. He joined Intradigm in 2007, having spent the previous 15 years in senior business development roles at several leading biotechnology companies including Genencor International, COR Therapeutics and Affymax/Affymetrix, among others. In these positions, he led the identification and negotiation of numerous collaborative and licensing agreements with a range of global and regional pharmaceutical companies. He most recently served as vice president, business development at Codexis, Inc. He possesses deep deal–making expertise that spans establishing discovery and development partnerships, technology and product in– and out–licensing, mergers and acquisitions, and financing support.

Dr. Haworth earned his J.D. from Stanford University Law School and his Ph.D. in biochemistry from the University of Manchester in the U.K. He also received his bachelor’s degree with first class honors in physiology and biochemistry from the University of Southampton in the U.K.

MAX HERRMANN
Position: Chief Financial Officer and Company Secretary
Mr. Herrmann possesses more than 20 years of biotechnology and pharmaceutical industry experience having held key management positions with leading development stage companies, as well as several investment banks.  In these roles, he has been involved in raising more than $300M for biotechnology companies in the United States and Europe.  Most recently Mr. Herrmann served as CFO of Intercytex Group plc, a publicly traded company focused on the emerging area of regenerative medicine.  Before joining Intercytex, he spent over ten years as a sell-side equity analyst, most recently as managing director and head of European pharmaceutical and biotechnology research at ING.  He has also held the position of financial controller for US-based Onyx Pharmaceuticals Inc and currently serves on the boards of Regenerative Medicine Assets Limited, as well as the company’s subsidiaries Intercytex Ltd. and Axordia Ltd.

Mr. Herrmann qualified as a Chartered Accountant with Arthur Andersen in 1993. He holds a degree in microbiology from the University of Kent.

KLAUS GIESE, Ph.D.
Position: Chief Scientific Officer
Dr. Giese has over 19 years of relevant experience in both the U.S. and Europe, including the management of more than 20 international collaborations with pharmaceutical and biotech companies and more than five years in cross-border management as CSO.  Dr. Giese joined Silence Therapeutics AG in 1999, where he continues his position as CSO. Prior to Silence Therapeutics, Dr. Giese was group leader at Chiron Corporation from 1994 to 1998 and was responsible for coordinating and managing a portion of Chiron's obesity and oncology program. His efforts in this program included the development of several different gene expression profiling approaches and the development of a novel high-throughput screening assay to identify inhibitors of HIV-1 transcription. Prior to joining Chiron, Dr. Giese acted as research scientist and postdoctoral fellow at the Howard Hughes Medical Institute, University of California, San Francisco, as well as at the Max-Planck-Institute for Molecular Genetics in Berlin. Dr. Giese studied biochemistry at the Free University of Berlin, where he also received his Ph.D.

MICHAEL RILEY, JD, M.Sc.
Position: Vice President of Intellectual Property & Corporate Development
Mr. Riley joined Silence in January 2010 as part of the company’s merger with Intradigm.  In the same position with Intradigm, he lead the company’s operations (finance, legal, HR & IT) while also holding responsibility for all intellectual property activities. Mr. Riley brings with him over 15 years of scientific, operational, intellectual property (legal) and international business experience. Most recently he held various positions in Europe and the U.S. with Amgen, Abgenix and Celltech Group PLC.

Mr. Riley obtained his JD with distinction from University of North Dakota School of law, and his M Sc from University of North Dakota School of Medicine, Department of Biochemistry and Molecular Biology.

THOMAS CHRISTÉLY
Position: Chief Operating Officer
Thomas Christély has more than 19 years experience in finance and corporate and business development. His track record includes multiple financing transactions, as well as M&A, divestments and strategic restructurings and more than nine years in cross-border management at board level. Mr. Christély joined Silence Therapeutics AG (Atugen AG) in 2001 as CFO and became COO in 2002 prior to being appointed its CEO in 2006. From 1996 to 2000, he held the position of senior vice president and CFO at OXO Chemie AG, a Swiss pharmaceutical company, and founded its subsidiary OXO Chemie, Inc., in San Francisco, where he stayed from 1997 to 2000. Mr. Christély was managing partner of the investment firm Löschen & Partner in Hamburg and Moscow, from 1992 to 1995 and worked in mergers and acquisitions of Enskilda Corporate Finance in London from 1989 to 1992. Mr. Christély has worked for two international accounting and consultancy firms and for the Commission of the European Union in Brussels. After his studies in Hamburg and Geneva, he received degrees in business administration (equivalent to MBA) and law from the University of Hamburg and was admitted as attorney-at-law.

• NanoViricides (OTCBB: NNVC)
• smartFOCUS Group (AIM: STF)